Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for non-type 2 chronic rhinosinusitis with nasal polyps
2023-505711-20-00Phase 4Completed
- Sponsor
- Tartu University Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of secukinumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Tartu University Hospital. Primary endpoints: Change in nasal polyp score (NPS) from baseline to week 16 and Change in SNOT-22 score from baseline to week 16. Started Aug 2023; status: completed.
02
Drugs
secukinumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2023-505711-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505711-20-00.